公开(公告)号：US11891365B2

公开(公告)日：2024-02-06

申请号：US17238321

申请日：2021-04-23

申请人： Valo Health, Inc.

发明人： Xiaozhang Zheng ,  Pui Yee Ng ,  Bingsong Han ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Cuixian Liu ,  Heather Davis ,  Aleksandra Rudnitskaya ,  David R. Lancia, Jr. ,  Kenneth W. Bair ,  David S. Millan ,  Matthew W. Martin

IPC分类号： A61K31/5513 ,  C07D267/14 ,  C07D291/08 ,  C07D413/06 ,  C07D419/06 ,  C07D413/12 ,  C07D413/04 ,  C07D267/12 ,  C07D243/14 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D498/04 ,  C07D498/08 ,  C07D493/08 ,  C07D413/08 ,  C07D491/107 ,  C07D495/10

CPC分类号： C07D267/14 ,  C07D243/14 ,  C07D267/12 ,  C07D291/08 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D413/04 ,  C07D413/06 ,  C07D413/08 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D491/107 ,  C07D493/08 ,  C07D495/10 ,  C07D498/04 ,  C07D498/08

摘要： The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:




where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

公开(公告)号：US11279681B2

公开(公告)日：2022-03-22

申请号：US17031814

申请日：2020-09-24

申请人： Valo Health, Inc.

发明人： Xiaozhang Zheng ,  Pui Yee Ng ,  Bingsong Han ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Cuixian Liu ,  Aleksandra Rudnitskaya ,  David R. Lancia, Jr. ,  David S. Millan ,  Matthew W. Martin ,  Kenneth W. Bair

IPC分类号： A61K31/55 ,  A61K31/554 ,  C07D223/16 ,  C07D281/02 ,  C07D281/10 ,  C07D471/04 ,  C07D513/04 ,  C07D267/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/04 ,  C07D267/12 ,  C07D243/14 ,  C07D291/08 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D413/14 ,  C07D417/04 ,  C07D498/04 ,  C07D498/08 ,  C07D493/08 ,  C07D413/08 ,  C07D491/107 ,  C07D495/10

摘要： The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

公开(公告)号：US12116362B2

公开(公告)日：2024-10-15

申请号：US17959064

申请日：2022-10-03

申请人： Valo Health, Inc.

发明人： Brian Raimundo ,  Elena S. Koltun ,  John Griffin ,  Eric Stangeland

IPC分类号： C07D417/14 ,  A61P1/16 ,  A61P3/10 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  C07D401/04 ,  C07D401/14 ,  C07D417/04 ,  C07D471/04

CPC分类号： C07D417/14 ,  A61P1/16 ,  A61P3/10 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  C07D401/04 ,  C07D401/14 ,  C07D417/04 ,  C07D471/04

摘要： Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.

公开(公告)号：US20240287031A1

公开(公告)日：2024-08-29

申请号：US18636832

申请日：2024-04-16

申请人： Valo Health, Inc.

发明人： Par HOLMBERG ,  Sumit KUMAR ,  Matthew James WATHIER ,  Huimin ZHAI ,  Christophe BENELLI ,  Xavier BON ,  Boris CAMUZAT-DEDENIS ,  Fabien RODIER

IPC分类号： C07D401/12

CPC分类号： C07D401/12

摘要： The invention relates to substituted 6-substituted isoquinoline oxide compounds of formula (V)




and to a process for making them. The compounds of formula (V) can be used as intermediates for making 6-substituted-1-(2H)-isoquinolinone compounds of formula (I)




The compounds of formula (I) are inhibitors of the enzyme Rho-kinase, or can be used as intermediates in the preparation of further inhibitors of the Rho-kinase enzyme.

公开(公告)号：US20230414585A1

公开(公告)日：2023-12-28

申请号：US18215887

申请日：2023-06-29

申请人： Valo Health, Inc.

发明人： Xiaozhang Zheng ,  Pui Yee Ng ,  Mary-Margaret Zablocki

IPC分类号： A61K31/438 ,  C07D401/04 ,  C07D221/20 ,  C07D401/06 ,  C07D209/54

CPC分类号： A61K31/438 ,  C07D401/04 ,  C07D221/20 ,  C07D401/06 ,  C07D209/54 ,  A61P25/14

摘要： The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

公开(公告)号：US20230346753A1

公开(公告)日：2023-11-02

申请号：US18073768

申请日：2022-12-02

申请人： Valo Health, Inc. ,  Genentech, Inc.

发明人： Kenneth W. Bair ,  Timm R. Baumeister ,  Alexandre J. Buckmelter ,  Karl H. Clodfelter ,  Peter Dragovich ,  Francis Gosselin ,  Bingsong Han ,  Jian Lin ,  Dominic J. Reynolds ,  Bruce Roth ,  Chase C. Smith ,  Zhongguo Wang ,  Po-Wai Yuen ,  Xiaozhang Zheng

IPC分类号： A61K31/4355 ,  C07D471/04 ,  C07D491/04 ,  C07D495/04 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/496 ,  A61K31/497 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D487/04 ,  C07D491/048

CPC分类号： A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/496 ,  A61K31/497 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/048 ,  C07D495/04

摘要： The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below:

公开(公告)号：US20230242512A1

公开(公告)日：2023-08-03

申请号：US17984065

申请日：2022-11-09

申请人： Valo Health, Inc.

发明人： Xiaozhang Zheng ,  Matthew W. Martin ,  Pui Yee Ng ,  Jennifer R. Thomason ,  Bingsong Han ,  Aleksandra Rudnitskaya ,  David R. Lancia, JR.

IPC分类号： C07D403/04 ,  C07D209/10 ,  C07D209/44 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

CPC分类号： C07D403/04 ,  C07D209/10 ,  C07D209/44 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

摘要： The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula:




wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.

公开(公告)号：US11702412B2

公开(公告)日：2023-07-18

申请号：US17124778

申请日：2020-12-17

申请人： Valo Health, Inc.

发明人： Xiaozhang Zheng ,  Pui Yee Ng ,  Aleksandra Rudnitskaya ,  David R. Lancia, Jr.

IPC分类号： C07D267/22 ,  C07D413/06 ,  C07D498/04 ,  A61P19/02 ,  A61P25/28 ,  A61P35/00

CPC分类号： C07D413/06 ,  C07D267/22

摘要： The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II:




where R, L, X1, X2, X3, X4, X5, Y1, Y2, Y3, and Y4 are described herein.

公开(公告)号：US20230143572A1

公开(公告)日：2023-05-11

申请号：US16952267

申请日：2020-11-19

申请人： Valo Health, Inc.

发明人： Roozbeh ASCHAR-SOBBI ,  Isabella PALLOTTA

IPC分类号： C12N5/071 ,  C12N5/077 ,  C12M3/00 ,  C12M1/32 ,  C12M1/34 ,  C12M1/42 ,  G01N33/50

CPC分类号： C12N5/0697 ,  C12N5/0658 ,  C12N5/0656 ,  C12M21/08 ,  C12M23/12 ,  C12M41/46 ,  C12M35/08 ,  C12M35/02 ,  G01N33/5088 ,  G01N33/5061 ,  C12N2513/00 ,  C12N2533/56 ,  C12N2533/54

摘要： Embodiments described herein relate generally to a three-dimensional ex vivo skeletal muscle tissue comprising a hydrogel and a plurality of cells that includes skeletal muscle cells, at least a portion of the cells being encapsulated inside the hydrogel. In some embodiments, the skeletal muscle tissue is characterized by one or more contractions in response to an electrical and/or chemical stimulation.

公开(公告)号：US20230113389A1

公开(公告)日：2023-04-13

申请号：US17798048

申请日：2021-02-03

申请人： Valo Health, Inc.

发明人： Roozbeh Aschar-Sobbi ,  Maw-Lin Kuo ,  Roger Stenerson ,  Winston Sun ,  Dickshitha Thyagharajon ,  Ya Kevin Thao ,  Chris Todd ,  Brian Wilfley

IPC分类号： C12M3/00 ,  C12M1/32 ,  C12M1/42 ,  C12M1/36 ,  C12M1/34

摘要： Embodiments described herein relate generally to devices, apparatuses, and systems with embedded electrodes for rowing, maintaining, and/or using 3D tissues in vitro. The devices, apparatuses, and systems described herein can provide scalable, automated tissue stimulation.